SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY FLASH L impact

Immuneering Presents Design of Ongoing Phase 3 MAPKeeper 301 Trial

Immuneering presented the design and methodology of its ongoing Phase 3 MAPKeeper 301 trial evaluating atebimetinib with modified gemcitabine/nab.

IMRXTEVA

Related stories